clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hernia, Hiatal D006551 3 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Hemophilia A D006467 10 associated lipids
Hemolysis D006461 131 associated lipids
Heart Failure D006333 36 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Hearing Disorders D006311 10 associated lipids
Hand Dermatoses D006229 5 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Giardiasis D005873 3 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Gastritis D005756 27 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Fractures, Open D005597 3 associated lipids
Foot Diseases D005534 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Haider RB et al. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. 2015 Eur J Gastroenterol Hepatol pmid:26287955
Shallom SJ et al. New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Group. 2015 J. Clin. Microbiol. pmid:26269619
Zagari RM et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. 2015 Dig Liver Dis pmid:26253555
Sprague J et al. Cutaneous infection with Mycobacterium kansasii in a patient with myelodysplastic syndrome and Sweet syndrome. 2015 Cutis pmid:26244358
Sharara AI et al. Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. 2015 Aliment. Pharmacol. Ther. pmid:26238584
Graham DY and Gisbert JP Letter: clarithromycin dose for H. pylori therapy remains unresolved. 2015 Aliment. Pharmacol. Ther. pmid:26238583
Navarro-Jarabo JM et al. Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain. 2015 Digestion pmid:26227669
Kasai A et al. Prevalence and molecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011. 2015 J. Med. Microbiol. pmid:25934551
Chou HW et al. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. 2015 Clin. Infect. Dis. pmid:25409476
Flores-Gonzalez JC et al. [Etiology, clinical presentation and outcome of severe viral acute childhood encephalitis (ECOVE study)]. 2015 Rev Neurol pmid:26108903
Jeong BH et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. 2015 Am. J. Respir. Crit. Care Med. pmid:25393520
Hill FJ et al. From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions. 2015 BMJ Case Rep pmid:26106178
Yu T et al. Study on clarithromycin lactobionate based dual selector systems for the enantioseparation of basic drugs in capillary electrophoresis. 2015 J Sep Sci pmid:26097042
Trotti LM et al. Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. 2015 Ann. Neurol. pmid:26094838
Tai WC et al. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication. 2015 Biomed Res Int pmid:26090428
Nguyen AT et al. Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections. 2015 Cornea pmid:26075451
Ito A et al. Increase in SCCmec type IV strains affects trends in antibiograms of meticillin-resistant Staphylococcus aureus at a tertiary-care hospital. 2015 J. Med. Microbiol. pmid:25934550
AktaÅŸ B et al. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies. 2015 Eur J Gastroenterol Hepatol pmid:25919773
Essilfie AT et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. 2015 Thorax pmid:25746630
Bouilhat N et al. High-level primary clarithromycin resistance of Helicobacter pylori in Morocco: a prospective multicenter molecular study. 2015 Helicobacter pmid:25735573
Guzman Vinasco L et al. Acute suppurative parotitis caused by Streptococcus pneumoniae in an HIV-infected man. 2015 BMJ Case Rep pmid:25733094
Mitsui Y et al. Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication. 2015 Clin J Gastroenterol pmid:25733031
Ben Chaabane N and Al-Adhba HS Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial. 2015 Indian J Gastroenterol pmid:25721770
Townsell MY et al. Pathology in practice. Canine distemper virus disease in a dog. 2015 J. Am. Vet. Med. Assoc. pmid:25719842
Scherübl H et al. [What is new in treating Helicobacter pylori infection?]. 2015 Dtsch. Med. Wochenschr. pmid:25704525
Aoki H et al. Clarithromycin highly-loaded gastro-floating fine granules prepared by high-shear melt granulation can enhance the efficacy of Helicobacter pylori eradication. 2015 Eur J Pharm Biopharm pmid:25703356
Blix HS et al. Antibiotic prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveillance? 2015 Epidemiol. Infect. pmid:25388750
Brown-Elliott BA et al. Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group, based on in vitro clarithromycin susceptibility. 2015 J. Clin. Microbiol. pmid:25568437
Amiri M Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura. 2015 Glob J Health Sci pmid:26925898
Haghi M et al. Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. 2015 Pharm. Res. pmid:25537341
Zhang L et al. [Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection]. 2015 Zhonghua Nei Ke Za Zhi pmid:26887366
Moriya S et al. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells. 2015 Int. J. Oncol. pmid:25422130
Montes M et al. Helicobacter pylori Infection in Children. Antimicrobial Resistance and Treatment Response. 2015 Helicobacter pmid:25382231
Park JB et al. Modulation of microenvironmental pH and utilization of alkalizers in crystalline solid dispersion for enhanced solubility and stability of clarithromicin. 2015 Arch. Pharm. Res. pmid:25213008
Anton E et al. Randomized Trial of Clarithromycin for Mediterranean Spotted Fever. 2015 Antimicrob. Agents Chemother. pmid:26711765
Winters N et al. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. 2015 Eur. Respir. J. pmid:26381514
Bang CS and Baik GH Time to learn from the past and prepare for the future in Helicobacter pylori eradication. 2015 Korean J. Intern. Med. pmid:26552453
Alimadadi M et al. Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease. 2015 Iran J Kidney Dis pmid:26552348
Karpiński TM et al. Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland. 2015 Acta Microbiol Immunol Hung pmid:26551571
John A et al. Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection? 2015 Indian J Gastroenterol pmid:26541342
Mel-Hennawi D and Ahmed MR Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. 2015 J Laryngol Otol pmid:26521817
Parra D et al. In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions. 2015 BMC Microbiol. pmid:26518881
Xing J et al. The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans. 2015 Anal. Chim. Acta pmid:26515003
Demirci H et al. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. 2015 Turk J Gastroenterol pmid:26510082
Bérard A et al. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. 2015 Pharmacoepidemiol Drug Saf pmid:26513406
Hwang JJ et al. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. 2015 World J. Gastroenterol. pmid:26401089
Weiss S et al. Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. 2015 Antimicrob. Agents Chemother. pmid:26392505
Agrawal V et al. A Case of Hypotension and Bradycardia Precipitated by Drug Interaction of Clarithromycin and Calcium-Channel Blocker. 2015 J Am Geriatr Soc pmid:26389998
Hauser G et al. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. 2015 Medicine (Baltimore) pmid:25929897
Glocker EO The Need for Resistance Surveillance and Antimicrobial Susceptibility Testing of Helicobacter pylori. 2015 Digestion pmid:26372776